11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine

11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine Suppliers list
Company Name: J & K SCIENTIFIC LTD.  
Tel: 18210857532 18210857532
Email: jkinfo@jkchemical.com
Company Name: ChemFuture PharmaTech (Jiangsu) Ltd  
Tel: 5108538618
Email: suger.wang@chemfuture.com
Company Name: Beijing HwrkChemical Technology Co., Ltd  
Tel: 89508211 18501085097
Email: sales.bj@hwrkchemical.com
Company Name: Capot Chemical Co., Ltd  
Tel: +86 (0) 571 85 58 67 18
Email:
Company Name: Daicel Chiral Technologies (China)CO.,LTD  
Tel: 021-50460086-9 15921403865
Email: han_yajun@dctc.daicel.com

11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine manufacturers

11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine Basic information
Product Name:11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine
Synonyms:11-Piperazinodibenzo[b,f][1,4]thiazepine;11-(Piperazin-1-yl);11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepine;2-(Piperazin-1-yl)dithiazepin;7-chloro-2-(2-methylphenyl)-3,1-benzoxazin-4-one;N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine;N-Des[2-(2-hydroxyethoxy)ethyl] QuetiapineDiscontinued See: D288740;Dibenzo[b,f][1,4]thiazepine, 11-(1-piperazinyl)-
CAS:5747-48-8
MF:C17H17N3S
MW:295.4
EINECS:
Product Categories:Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
Mol File:5747-48-8.mol
11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine Structure
11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine Chemical Properties
Boiling point 465.2±55.0 °C(Predicted)
density 1.30
storage temp. Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility DMF: 16 mg/mL; DMSO: 3 mg/mL; Ethanol: 5 mg/mL; PBS (pH 7.2): 0.25 mg/mL
form A solid
pka8.55±0.10(Predicted)
Safety Information
HazardClass IRRITANT
MSDS Information
11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine Usage And Synthesis
Chemical PropertiesPale-Yellow Solid
Uses11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine is a metabolite of Quetiapine, a Benzothiazepine with mixed serotonin and dopamine receptor antagonistic properties used as an antipsychotic.
DefinitionChEBI: Norquetiapine is a dibenzothiazepine.
Synthesis
11-(1-PIPERAZINYL)-DIBENZO[B,F][1,4]THIAZEPIN HYDROCHLORIDE

753475-15-9

11-(PIPERAZIN-1-YL)DIBENZO[B,F][1,4]THIAZEPINE

5747-48-8

General procedure for the synthesis of 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine from 11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine hydrochloride: a toluene solution of 11-chloro-dibenzo[b,f][1,4]thiazepine (1500 mL, 0.686 mol) was mixed with 1500 mL of deionized water and 90 mL of HCl (32% w/w) were mixed. The reaction mixture was heated to 70 °C and stirred for 45 min. Stirring was stopped and allowed to stand for 30 minutes for phase separation. The lower aqueous phase was separated, which contained the HCl salt of 11-piperazin-1-yl dibenzo[b,f][1,4]thiazepine. Subsequently, the aqueous phase was treated with 1000 mL of toluene and 99 g aqueous NaOH (47% w/w). The mixture was heated to 70 °C and stirred for 45 min. Stirring was stopped and allowed to stand for 30 min for phase separation. The lower aqueous phase was discarded, the upper organic phase was retained and 300 mL of deionized water was added to it. The mixture was stirred for 15 minutes and then allowed to stand for 30 minutes. The aqueous phase was discarded and the organic phase was again extracted with 300 mL of deionized water. Approximately 750 mL of toluene was removed by distillation and the concentrate was cooled to 60°C. 200 mL of methyl tertiary butyl ether (MTBE) was added. The mixture was cooled to room temperature and inoculated with Type A crystalline seed. Subsequently, the mixture was cooled to 10 °C and kept under slow stirring for 3 hours. The solid product was separated by filtration through a #3 sintered funnel. The solid was washed with 120 mL of MTBE at room temperature and finally dried under vacuum at 40 °C to give 175 g (86.4% yield) of crystalline product.HPLC analysis showed a product purity of 99.9% w/w.

References[1] Patent: WO2006/73360, 2006, A1. Location in patent: Page/Page column 10-11
[2] Patent: WO2006/73360, 2006, A1. Location in patent: Page/Page column 10
[3] Patent: WO2007/62338, 2007, A2. Location in patent: Page/Page column 13-14
[4] Patent: WO2007/62337, 2007, A2. Location in patent: Page/Page column 13-14
[5] Patent: WO2007/62337, 2007, A2. Location in patent: Page/Page column 14
Tag:11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine(5747-48-8) Related Product Information
11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepin hydrochloride Ethanol, 2-[2-[4-(5-oxidodibenzo[b,f][1,4]thiazepin-11-yl)-1-piperazinyl]ethoxy]- ,dihydrochloride 11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine N-Des[2-(2-hydroxyethoxy)ethyl] quetiapine-d8 11-[4-(2-Chloro-ethyl)-piperazin-1-yl]-dibenzo[b,f][1,4]thiazepine 7-Hydroxy quetiapine 11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepin-7-ol Quetiapine sulfoxide Quetiapine Metiapine 11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepine dihydrochloride 11-(1-Piperazinyl-d8)-dibenzo[b,f][1,4]thiazepin-7-ol 7-Hydroxy Quetiapine-D8 CLOTHIAPINE Quetiapine fumarate